T-cell receptor (on CD8-positive T lymphocyte) (TCR (on CD8+ T cell))

The T-cell receptor (TCR) on CD8-positive T lymphocytes is a heterodimeric transmembrane protein complex composed primarily of alpha and beta chains, responsible for recognizing short peptide antigens presented on major histocompatibility complex class I (MHC-I) molecules on target cells[4][5][7]. CD8 acts as a co-receptor, stabilizing the TCR-MHC-I interaction and facilitating signal transduction essential for T cell activation, cytotoxic function, and immune memory[2][3][4]. Engagement of the TCR with its cognate antigen leads to activation of a signaling cascade via the associated CD3 complex, ultimately driving immune responses such as cell-mediated killing of virally infected or transformed cells, orchestration of adaptive immunity, and memory formation[4][5][7]. The central role of the TCR in antigen recognition and the regulation of T cell function make it a crucial therapeutic target and biomarker in immuno-oncology, infection, and autoimmune disease research. Additional context: - TCRs are highly diverse due to recombination events that create unique antigen-binding sites, enabling the immune system to recognize a vast array of pathogens[4][5]. - Therapeutic interventions typically target or harness TCR signaling pathways rather than the TCR itself, through immune checkpoint modulation, CAR-T cell engineering, or immunosuppressive drugs[2][4][5]. - Aberrant or dysregulated TCR signaling is implicated in autoimmunity, immune deficiency, and cancer immune evasion[2][7].

Other names

TCR on cytotoxic T cellTCR on CD8+ T cellcytotoxic T cell TCRTCR (CD8+)T lymphocyte receptor (CD8+)

Enhancement or suppression of TCR-mediated signaling (e.g., by modulating co-receptors or downstream kinases) Induction of T-cell activation or anergy (loss of response) Promotion of cytotoxic T cell-mediated killing of target cells (tumor or infected cells) Inhibition of T-cell proliferation or effector function for immunosuppression